Nicox to present at the Stifel 2015 Healthcare Conference


Nicox to present at the Stifel 2015 Healthcare Conference

...................................

November 13, 2015

Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0000074130, COX), today announced that Michele Garufi, Chairman and CEO of Nicox, will be presenting at the Stifel 2015 Healthcare Conference in New York City on Wednesday November 18, 2015, at 11:45 am EST (5:45pm CET) .

A live webcast of the presentation can be accessed under the "Presentations & webcasts" page within the News & Media section of the company's website at www.nicox.com. A replay of the webcast will be archived on the Nicox website for 90 days following the date of the presentation.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight.

Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was recently submitted to the FDA by the Company's licensee Valeant. Our pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe's five largest markets complemented by an expanding international network of distributors.

Nicox is headquartered in France and has more than 130 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com.

...................................

Upcoming 2015 events

Financial and business conferences

Nov. 20-21    Actionaria 2015                                                    Paris, France

Scientific conferences

Nov. 14-17    AAO - American Academy of Ophthalmology                        Las Vegas, US
Nov. 27-30    SOI National Congress                                       Rome, Italy  

Analyst coverage

Bryan, Garnier & Co       Hugo Solvet                    Paris, France
Stifel                                 Max Herrmann                London, UK
Invest Securities             Martial Descoutures       Paris, France
Kepler Cheuvreux           Alexandra Ralli               Paris, France

 
  

...................................
Contacts

Nicox                              Gavin Spencer | Executive Vice President Corporate Development
                                        Caroline Courme | Communication Manager
                                        Tel +33 (0)4 97 24 53 43 | communications@nicox.com    

Media Relations           

United Kingdom               Jonathan Birt
                                        Tel +44 7860 361 746 | jonathan.birt@ymail.com

France                            NewCap | Nicolas Merigeau
                                        Tel +33 (0)1 44 71 94 98 | nicox@newcap.fr  

United States                  Argot Partners | Eliza Schleifstein
                                        Tel +1 (917) 763-8106 | eliza@argotpartners.com

Investor Relations       

Europe                            NewCap | Julien Perez | Valentine Brouchot
                                        Tel +33 (0)1 44 71 94 94 | nicox@newcap.fr

United States                  Argot Partners | Melissa Forst
                                        Tel +1 (212) 600-1902 | melissa@argotpartners.com
...................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2014' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website (www.nicox.com).

Nicox S.A. Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France T: +33 (0)4 97 24 53 00   |   F: +33 (0)4 97 24 53 99  www.nicox.com   


Anhänge

FOR INFORMATION